Evidence map›Paper›PMID 41487784›Full record

ArticleCureus2025

Late Onset of Entrectinib-Related ST Elevation in the Setting of Alcohol Intoxication in a Patient With Metastatic Non-small Cell Lung Cancer: A Case Report and Literature Review.

Chenfan Xia, Suzanne Kosmider

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chenfan XiaDepartment of Oncology, Western Health, Melbourne, AUS.
Suzanne KosmiderDepartment of Oncology, Western Health, Melbourne, AUS.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report describes a case of a 56-year-old male with non-small cell lung cancer who had been on entrectinib 600 mg daily for five years. He presented with an acute onset of chest pain associated with transient ST elevation and troponin rise in the context of alcohol intoxication. He was investigated with a coronary artery angiogram, a transthoracic echocardiogram, and a cardiac magnetic resonance imaging, which were all unremarkable. The ST elevation resolved after withholding entrectinib for two days. Given that no other cause was identified, it suggests that entrectinib may be the potential cause. Considering the patient's good response to entrectinib in the past, we recommenced entrectinib at a reduced dose of 400 mg daily after withholding it for three weeks. This late onset of ECG changes after such a prolonged treatment duration has not been reported previously, and the underlying mechanism remains unclear. It is also uncertain whether heavy alcohol intake is a contributing factor. Further research is needed to investigate the long-term cardiac toxicity of entrectinib and the potential interactions between entrectinib and alcohol.

Indexed as

alcohol-related disordercancer treatment side effectscardiac arrhythmiaentrectinibnon-small cell lung carcinoma (nsclc)ros1 gene fusionros1-positive nsclcst elevation ecgtargeted therapytyrosine kinase inhibitor (tki)

Identifiers

PMID41487784
PMCPMC12757655

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.